Literature DB >> 8712567

Operations for gastric ulcer: a long-term study.

M P McDonald1, T A Broughan, R E Hermann, R S Philip, S O Hoerr.   

Abstract

This study assesses the long-term results of operations for benign gastric ulcers. Three-hundred forty-nine patients operated upon between 1950-1979 have been followed over the past 20 years with a mean and median follow-up of 11.8 and 11.1 years. Fifty-five per cent of the patients had a gastric resection without vagotomy; 19.8 per cent had gastric resection with vagotomy; and 20.3 per cent had vagotomy, pyloroplasty, and wedge excision or biopsy of the ulcer. Operations were selected based on the type of ulcer (Types 1-4), whether the surgeon suspected cancer preoperatively, whether the operations was elective or an emergency, and the age and general health of the patient (presence of significant co-morbid disease). Overall mortality was 6.9 per cent, with a mortality for elective operations 3.6 per cent, and for emergency operations of 32.5 per cent. Age and cardiovascular disease were significant factors in operative mortality and morbidity. All operations were equivalent in long-term results. Excellent to good results were obtained in 92 per cent of patients, with an ulcer recurrence rate of 4 per cent. We conclude that vagotomy, pyloroplasty, and wedge excision or biopsy of a benign gastric ulcer is a comparable operation to a more major gastric resection, with or without vagotomy, in the surgical management of gastric ulcer. The addition of vagotomy to gastric resection does not appear to improve long-term results.

Entities:  

Mesh:

Year:  1996        PMID: 8712567

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  1 in total

1.  The surgical management of complicated peptic ulcer disease: An EAST video presentation.

Authors:  Aaron Hudnall; James M Bardes; Kennith Coleman; Conley Stout; Daniel Regier; Stephen Balise; David Borgstrom; Daniel Grabo
Journal:  J Trauma Acute Care Surg       Date:  2022-04-01       Impact factor: 3.697

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.